Sign up
Pharma Capital
EPIC: ELBIM
Market: PRIVATE-UK
Sector: Pharma & Biotech
Website: elpis.ltd

Elpis Biomed is a cell science company. We are a spin-out from the Laboratory of the Wellcome Trust MRC Cambridge Stem Cell Institute at the University of Cambridge. We have a team of world-leading scientists passionate about high-quality research and taking human cell culture to the next level. Our mission is to enable science, drug discovery, and the development of cell therapies by...

Elpis BioMed Ltd

elpis.ltd

Interactive graph

col 3
col 4
col 5
col 6

Elpis BioMed Ltd Snapshot

Elpis BioMed’s proprietary platform technology genetically hard-wires cellular differentiation into stem cells to provide highly pure and mature human cell types in unlimited quantities. What makes the technology truly unique is:

1. It is highly efficient. Pluripotent cells convert into the desired cell type within 4-7 days, and can be used for experiments within 2 days of plating.
2. New cell types can be generated with greater precision and ease. We are rapidly expanding our product portfolio and are able to develop novel cell types that do not yet exist within 14-18 months.
3. Superior purity and consistency. Our reprogramming process is highly synchronised ensuring that the cells are at the same stage of maturity. Our cultures do not require purification steps as they consist of a single cell type only.

We are able to create custom disease models and cell lines for your specific research needs.

Product: Human-induced cortical neurons

Elpis cortical neurons are derived from hiPSCs by using the OPTi-OX system. Elpis has produced homogenous, controllable, and extremely high expression of inducible transgenes NGN2 hIPSCs. These cells, on addition of doxycycline, differentiate within days into pure, mature and functional cortical neurons. Elpis’ neurons are ready-to-culture, for research use. These neurons are suitable as models for research in cell-type specific biology, target validation and drug screening in pharmaceutical R&D, and screening for toxicology. Applications include functional and general neurotoxicity assays. Our cortical neurons are pure (>99%), easy to culture and ready for use without requiring cumbersome cell culture work. Batch-to-batch consistency has ensured that the cortical neurons have been successfully used in very demanding screening conditions where only small changes had to be picked up from background noise.

Video Player
 
00:00
 
00:22

Advantages of Elpis cortical neurons

Highly pure population

Fast maturation

Early electrical signal

Easy culturing

REQUEST A QUOTE

 

Production Specification

Catalogue no.: e0101a
Manufacture site: United Kingdom
Product code:  
Size: 1x10^6 cells
Product use: iCONE1 are for research use only. It is not approved for human or animal use, or for application in in vitro diagnostic procedures
Storage: Upon receiving, directly and immediately transfer the cells from dry ice to liquid nitrogen and keep the cells in liquid nitrogen until they are needed for experiments
Shipping info: Dry Ice

Supported applications


  • Drug screens
  • Genetic screens
  • Chromatin immunoprecipitation
  • Patch clamp and EMA
 

 


 

 

Product: Human-induced myocytes

Elpis induced myocytes are derived from hiPSCs by using the OPTi-OX system. These cells, on addition of doxycycline, differentiate within days into pure, mature and functional multinucleated myocytes. Elpis myocytes are ready-to-culture for research use. They are suitable as models for research in cell-type specific biology, target validation and drug screening in pharmaceutical R&D, and screening for toxicology. Applications include functional and general toxicity assays. Our myocytes are pure (>99%), easy to culture and ready for use without requiring cumbersome cell culture work. Batch-to-batch consistency has ensured that the myocytes can be successfully used in very demanding screening conditions where only small changes have to be picked up from background noise.

Video Player
 
00:00
 
00:39

Advantages of Elpis myocytes

Highly pure population

Mature multinucleated cells

Fast maturation

Easy culturing

REQUEST A QUOTE

 

Product specification

Catalogue no.: e0102a
Manufacture site: United Kingdom
Product code:  
Size: 1x10^6 cells
Product use: These cells are for research use only. It is not approved for human or animal use, or for application in in vitro diagnostic procedures
Storage: Upon receiving, directly and immediately transfer the cells from dry ice to liquid nitrogen and keep the cells in liquid nitrogen until they are needed for experiments
Shipping info: Dry Ice

Supported applications


  • Drug screens
  • Genetic screens
  • Chromatin immunoprecipitation
  • Contraction assays
 

 


 

 

Your partner for custom cell type development

Elpis has developed an ultra-fast method for generating mature and highly pure human cell types. These cells are ideal for biomedical research, drug discovery and cell therapy.

  Directed differentiation Reprogramming
Ease of culture Complex culture Simple culture using standard media
Culture time 6-30 weeks 5-7 days
Purity 10-80% 95-100%
Consistency Highly variable Highly consistent

Disease model development package (4-6 months)

As part of this package, we can generate custom disease&

Mark Kotter
Founder/Director

Gordana Apic
Commercial Director

Jonathan Milner
Investor Director

Imbisaat Geti
Head of Manufacturing

Roger Pedersen
Chief Scientific Advisor

How to find us

We are based at ideaSpace South, which is part of the Addenbrooke’s Campus in Cambridge. Our address is below.

University of Cambridge Biomedical Innovation Hub
Clifford Allbutt Building
Cambridge Biomedical Campus
Hills Road
Cambridge, CB2 0AH
United Kingdom

Getting in touch

If you have any questions or would like to discuss quotes for potential projects, please get in touch.

Our email is [email protected]

View full ELBIM profile View Profile
View All

Market Reports Including ELBIM

VIEW ALL

Executive video interviews

VIEW ALL VIDEOS

© biotech Capital 2019

Biotech Capital, a subsidiary of Proactive Investors, acts as the vanguard for listed biotech companies to interact with institutional and highly capitalised investors.
Headquartered in London, Biotech Capital is led by a team of Europe's leading analysts and journalists, publishing daily content, covering all key movements in the Biotechnology market.